Artesunate-clindamycin versus quinine-clindamycin in the treatment of Plasmodium falciparum malaria: a randomized controlled trial.

@article{Ramharter2005ArtesunateclindamycinVQ,
  title={Artesunate-clindamycin versus quinine-clindamycin in the treatment of Plasmodium falciparum malaria: a randomized controlled trial.},
  author={Michael Ramharter and Sunny Oyakhirome and Peter M. C. Klein Klouwenberg and Ay{\^o}la A. Adegnika and Selidji Todagbe Agnandji and Michel Anoumou Missinou and Pierre-Blaise Matsi{\'e}gui and Benjamin Mordm{\"u}ller and Steffen Borrmann and J{\"u}rgen F. J. Kun and Bertrand Lell and Sanjeev Krishna and Wolfgang Graninger and Saadou Issifou and Peter Gottfried Kremsner},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2005},
  volume={40 12},
  pages={1777-84}
}
BACKGROUND Artemisinin-based drug combinations are the mainstay in the fight against drug-resistant malaria in Africa. Currently available antimalarial drug combinations that include artemisinins are pharmacokinetically unmatched and are therefore potentially increasing the risk of selection of resistant mutants in areas in which the rate of transmission of malaria is high. We tested the potential value of artemisinin-based combination therapy with a short elimination half-life for the… CONTINUE READING